BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory of tons in a single day. The Federal Trade Commission doesn't think that's significant." Hunt used this real-life message as an inoculation treatment in his research (Lessne and Didow, 1987). He used the corrective campaign by the FTC as the attack on the positive attitude toward Chevron. The results indicated that a supportive treatment offered less resistance than a refutational treatment. The other discovery was that when an inoculative treatment is received, but no attack is followed there is a drop in attitude. One of the major limitations in this study was that Hunt did not allow a time elapse